Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.00 | 0.74% | 1,488.50 | 1,486.00 | 1,486.50 | 1,491.00 | 1,476.50 | 1,478.00 | 5,748,076 | 16:35:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 31.38B | 2.58B | 0.6211 | 23.93 | 61.26B |
From Mar 2020 to Mar 2025
--GlaxoSmithKline PLC won't be pushed into a sale of its vaccines and pharmaceuticals business by activist U.S. hedge fund Elliott Management, The Times of London reports.
--Elliott isn't planning to agitate for reducing the pharmaceutical giant's 5 billion-pound ($7.06 billion) research and development budget and will back GlaxoSmithKline staying in the U.K., The Times says.
--Speculation had been raised by investors and analysts over Elliott's intentions after it was discovered in April that the activist fund had acquired a multi-billion pound stake in the company, The Times reports.
Full story: https://bit.ly/3i05I4y
Write to Barcelona editors at barcelonaeditors@dowjones.com
(END) Dow Jones Newswires
May 27, 2021 01:26 ET (05:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
